Diabetes, Vol 35, Issue 6 675-683, Copyright © 1986 by American Diabetes Association

ARTICLES

Purification and characterization of insulin-degrading enzyme from human erythrocytes

K Shii, K Yokono, S Baba and RA Roth

An insulin-degrading enzyme (IDE) was purified from the cytosol of human erythrocytes via the use of ammonium sulfate precipitation and chromatography on columns composed of DEAE-Sephadex, pentylagarose, hydroxylapatite, chromatofocusing resins, and Ultrogel AcA-34. The final preparation was purified greater than 50,000-fold and exhibited a single protein band of Mr = 110,000 on reduced sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. Cross-linking of 125I-labeled insulin to the enzyme preparation labeled a protein of the same molecular weight, indicating that this band was in fact the enzyme. Intact insulin, insulin B chain, and glucagon inhibited this cross-linking half-maximally at concentrations of 0.1, 1, and 1.5 microM, respectively. Under nondenaturing conditions, the enzyme had an Mr = 300,000, suggesting that the enzyme may exist under physiological conditions as a dimer or timer. The purified enzyme was inhibited by both sulfhydrylmodifying reagents and chelating agents, indicating that a free thiol and metal were both required for the activity of the enzyme. The purified enzyme was found to degrade physiological concentrations of intact insulin more rapidly than insulin B chain, although at high substrate concentrations (greater than 1 microM) the enzyme degraded B chain to a greater extent. Additional characteristics of the enzyme were a pl of 5.2 and a pH optimum of 7.0. These properties of the red blood cell (RBC) enzyme were very similar to those reported for IDEs from other tissues. Moreover, a polyclonal antiserum to the IDE from skeletal muscle was found to recognize the RBC enzyme.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. E. Llovera, M. de Tullio, L. G. Alonso, M. A. Leissring, S. B. Kaufman, A. E. Roher, G. de Prat Gay, L. Morelli, and E. M. Castano The Catalytic Domain of Insulin-degrading Enzyme Forms a Denaturant-resistant Complex with Amyloid {beta} Peptide: IMPLICATIONS FOR ALZHEIMER DISEASE PATHOGENESIS J. Biol. Chem., June 20, 2008; 283(25): 17039 - 17048. [Abstract] [Full Text] [PDF]

				C. E. Murata and D. E. Goldberg Plasmodium falciparum Falcilysin: A METALLOPROTEASE WITH DUAL SPECIFICITY J. Biol. Chem., September 26, 2003; 278(39): 38022 - 38028. [Abstract] [Full Text] [PDF]

				M.C. Camberos, A.A. Pérez, D.P. Udrisar, M.I. Wanderley, and J.C. Cresto ATP Inhibits Insulin-Degrading Enzyme Activity Experimental Biology and Medicine, April 1, 2001; 226(4): 334 - 341. [Abstract] [Full Text]

				F. Authier, G. M. Danielsen, M. Kouach, G. Briand, and G. Chauvet Identification of Insulin Domains Important for Binding to and Degradation by Endosomal Acidic Insulinase Endocrinology, January 1, 2001; 142(1): 276 - 289. [Abstract] [Full Text] [PDF]

				K. K. Eggleson, K. L. Duffin, and D. E. Goldberg Identification and Characterization of Falcilysin, a Metallopeptidase Involved in Hemoglobin Catabolism within the Malaria Parasite Plasmodium falciparum J. Biol. Chem., November 5, 1999; 274(45): 32411 - 32417. [Abstract] [Full Text] [PDF]

				D. Chevenne, A. Letailleur, F. Trivin, and D. Porquet Effect of Hemolysis on the Concentration of Insulin in Serum Determined by RIA and IRMA Clin. Chem., February 1, 1998; 44(2): 354 - 356. [Full Text] [PDF]

				R. G. Bennett, W. C. Duckworth, and F. G. Hamel Degradation of Amylin by Insulin-degrading Enzyme J. Biol. Chem., November 17, 2000; 275(47): 36621 - 36625. [Abstract] [Full Text] [PDF]